Chemicals · Founded 2003 · www.anupamrasayan.com · BSE 543275 · NSE ANURAS · ISIN INE930P01018
No Notes Added Yet
Business
Anupam Rasayan India Ltd. (ARIL) is a leading specialty chemical manufacturer in India, primarily engaged in custom synthesis and manufacturing of specialty chemicals for various end-user industries. The company focuses on highly complex, multi-step synthesis and differentiated chemicals. Its core business model involves developing and manufacturing advanced intermediates and active ingredients based on proprietary chemistries or customer-provided specifications. It generates revenue by supplying these specialty chemicals, often under long-term contracts, to global agrochemical, pharmaceutical, pigment, and personal care companies.
Revenue Mix
Anupam Rasayan's revenue is primarily derived from two broad segments:
Life Science Related Specialty Chemicals: This segment caters to agrochemicals (herbicides, fungicides, insecticides), pharmaceuticals, and animal health products. This is historically its dominant segment.
Other Specialty Chemicals: This segment includes specialty pigments, dyes, and chemicals for personal care products.
The company typically serves a mix of multinational corporations and domestic players, with a significant portion of its revenue derived from exports. Specific revenue contribution percentages for each segment are not constant but the life sciences segment typically accounts for a larger share.
Industry
The Indian specialty chemicals industry is characterized by its diversity, high growth potential, and increasing global prominence due to factors like cost-effectiveness, skilled manpower, and robust R&D capabilities. Anupam Rasayan operates in the niche of custom synthesis and manufacturing (CSM) of advanced intermediates and complex molecules. It is positioned as a reliable partner for global companies seeking to outsource complex chemical synthesis, particularly in agrochemicals and pharmaceuticals. Its positioning is strengthened by its focus on challenging chemistries, robust R&D, and ability to scale up production.
MOAT
Process Intensification & R&D Capabilities: Expertise in handling complex, hazardous, and multi-step reactions, supported by strong in-house R&D capabilities, allows it to develop and scale niche chemical processes.
Long-term Customer Relationships: Strong and sticky relationships with global customers, often spanning decades, due to consistent quality, reliability, and confidentiality in custom synthesis projects.
Diversified Product Portfolio: While focused on specialty chemicals, its products cater to multiple end-user industries, reducing dependence on a single sector.
Backward Integration: Strategic backward integration for key raw materials helps in cost optimization and supply chain stability.
Growth Drivers
Increasing Outsourcing Trend: Global chemical majors are increasingly outsourcing manufacturing of complex intermediates to Indian players, driven by cost efficiencies and environmental regulations in developed economies.
End-Market Growth: Growing demand from key end-user industries such as agrochemicals (for crop protection), pharmaceuticals (for new drug development), and pigments globally.
Capacity Expansion: Ongoing capital expenditure and expansion projects to meet growing demand and diversify product offerings.
New Product Development & Diversification: Focus on developing new molecules and expanding into newer specialty chemical segments, including electronic chemicals and personal care.
Risks
Raw Material Price Volatility: Fluctuations in crude oil prices and other key raw material costs can impact profitability, as it has limited ability to pass on all cost increases.
Client Concentration: While diversified, a significant portion of revenue may still come from a few large multinational clients, making it vulnerable to changes in their procurement strategies.
Regulatory & Environmental Risks: Strict environmental regulations, hazardous waste management, and potential changes in chemical policies can lead to increased compliance costs or operational disruptions.
Forex Fluctuations: A significant portion of revenue is export-oriented, making it susceptible to adverse currency movements.
Competition: Intense competition from domestic and international specialty chemical manufacturers.
Management & Ownership
Anupam Rasayan is a promoter-driven company. The Shah family are the promoters with Mr. Anand S. Desai and Mr. Milan S. Thakkar serving as Managing Directors. The promoters have a long history and deep understanding of the chemical industry, having been involved in specialty chemical manufacturing for several decades. Promoter holding typically reflects a significant stake, aligning their interests with the company's long-term growth. The management team includes experienced professionals in R&D, operations, and sales.
Outlook
Anupam Rasayan is well-positioned to capitalize on the secular growth trends in the Indian specialty chemicals sector, driven by global outsourcing and increasing demand from its key end-user industries. Its strong R&D capabilities, long-standing customer relationships, and strategic capacity expansions provide a robust foundation for future growth. However, the company faces potential headwinds from raw material price volatility, intense competition, and the inherent regulatory complexities of the chemical industry. While the company's focus on complex chemistries and diversification into new segments offers resilience, managing client concentration and effectively passing on input cost increases will be crucial for sustained profitability.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 296 | 401 | 254 | 294 | 390 | 500 | 486 | 731 | 512 | 636 |
| Other Income | 2 | 12 | 6 | 2 | -4 | 6 | 5 | 8 | 2 | 3 |
| Total Income | 298 | 413 | 260 | 296 | 387 | 506 | 491 | 739 | 515 | 639 |
| Total Expenditure | 216 | 308 | 201 | 214 | 266 | 356 | 362 | 596 | 385 | 498 |
| Operating Profit | 81 | 105 | 59 | 82 | 121 | 150 | 129 | 144 | 130 | 141 |
| Interest | 25 | 26 | 22 | 27 | 32 | 31 | 36 | 36 | 35 | 42 |
| Depreciation | 20 | 21 | 21 | 22 | 29 | 31 | 31 | 32 | 34 | 43 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 36 | 58 | 16 | 34 | 59 | 88 | 63 | 76 | 60 | 56 |
| Provision for Tax | 10 | 17 | 4 | 3 | 5 | 25 | 14 | 18 | -1 | 0 |
| Profit After Tax | 26 | 40 | 12 | 31 | 54 | 63 | 48 | 57 | 61 | 56 |
| Adjustments | -8 | -10 | -8 | -14 | -26 | -18 | -14 | -13 | -12 | -13 |
| Profit After Adjustments | 18 | 31 | 4 | 17 | 28 | 45 | 34 | 44 | 49 | 43 |
| Adjusted Earnings Per Share | 1.7 | 2.8 | 0.4 | 1.5 | 2.6 | 4.1 | 3.1 | 3.9 | 4.3 | 3.7 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 288 | 288 | 343 | 501 | 529 | 811 | 1074 | 1602 | 1475 | 1437 | 2365 |
| Other Income | 8 | 11 | 6 | 20 | 17 | 27 | 7 | 9 | 30 | 16 | 18 |
| Total Income | 296 | 299 | 349 | 521 | 545 | 838 | 1081 | 1610 | 1505 | 1453 | 2384 |
| Total Expenditure | 208 | 218 | 268 | 408 | 400 | 617 | 769 | 1171 | 1094 | 1041 | 1841 |
| Operating Profit | 87 | 81 | 81 | 113 | 146 | 220 | 312 | 440 | 411 | 412 | 544 |
| Interest | 21 | 21 | 15 | 24 | 45 | 69 | 31 | 63 | 89 | 112 | 149 |
| Depreciation | 13 | 15 | 18 | 23 | 29 | 52 | 60 | 71 | 80 | 102 | 140 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 54 | 45 | 49 | 66 | 72 | 100 | 222 | 308 | 242 | 198 | 255 |
| Provision for Tax | 11 | 10 | 9 | 16 | 18 | 30 | 70 | 91 | 74 | 38 | 31 |
| Profit After Tax | 43 | 35 | 40 | 50 | 53 | 70 | 152 | 217 | 167 | 160 | 222 |
| Adjustments | 0 | 0 | 1 | -1 | 0 | 0 | 0 | -36 | -39 | -67 | -52 |
| Profit After Adjustments | 43 | 35 | 41 | 49 | 53 | 70 | 152 | 181 | 129 | 93 | 170 |
| Adjusted Earnings Per Share | 8.5 | 7 | 8.2 | 9.8 | 10.6 | 7 | 15.2 | 16.8 | 11.7 | 8.5 | 15 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -3% | 10% | 22% | 0% |
| Operating Profit CAGR | 0% | 10% | 23% | 0% |
| PAT CAGR | -4% | 2% | 25% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 27% | 6% | 11% | NA% |
| ROE Average | 6% | 8% | 8% | 12% |
| ROCE Average | 8% | 10% | 10% | 11% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 147 | 250 | 457 | 507 | 594 | 1573 | 1727 | 2373 | 2761 | 2850 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 135 | 170 | 231 |
| Borrowings | 164 | 223 | 268 | 462 | 525 | 247 | 494 | 355 | 197 | 171 |
| Other Non-Current Liabilities | 7 | 9 | 10 | 14 | 52 | 57 | 74 | 104 | 158 | 208 |
| Total Current Liabilities | 163 | 151 | 266 | 341 | 500 | 429 | 595 | 811 | 1316 | 1808 |
| Total Liabilities | 481 | 632 | 1001 | 1324 | 1670 | 2307 | 2891 | 3778 | 4602 | 5269 |
| Fixed Assets | 259 | 313 | 382 | 681 | 977 | 1115 | 1202 | 1417 | 1501 | 2185 |
| Other Non-Current Assets | 70 | 94 | 281 | 218 | 135 | 92 | 242 | 249 | 874 | 511 |
| Total Current Assets | 152 | 226 | 338 | 425 | 558 | 1099 | 1447 | 2111 | 2227 | 2573 |
| Total Assets | 481 | 632 | 1001 | 1324 | 1670 | 2307 | 2891 | 3778 | 4602 | 5269 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 15 | 8 | 7 | -2 | 17 | 241 | 48 | 188 | 250 |
| Cash Flow from Operating Activities | 69 | 17 | -22 | 39 | 95 | 1 | -171 | 292 | 59 | -30 |
| Cash Flow from Investing Activities | -168 | -93 | -255 | -250 | -178 | -193 | -412 | -523 | -392 | -330 |
| Cash Flow from Financing Activities | 115 | 73 | 277 | 206 | 102 | 416 | 384 | 371 | 395 | 223 |
| Net Cash Inflow / Outflow | 15 | -3 | -1 | -6 | 19 | 224 | -199 | 140 | 62 | -137 |
| Closing Cash & Cash Equivalent | 15 | 12 | 7 | 2 | 17 | 241 | 42 | 188 | 250 | 113 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 8.53 | 6.96 | 8.17 | 9.85 | 10.64 | 7.04 | 15.18 | 16.83 | 11.71 | 8.49 |
| CEPS(Rs) | 11.04 | 10.03 | 11.49 | 14.55 | 16.38 | 12.2 | 21.18 | 26.79 | 22.51 | 23.86 |
| DPS(Rs) | 0.5 | 0 | 0 | 0 | 0 | 0.5 | 1.5 | 2.5 | 1.25 | 0.75 |
| Book NAV/Share(Rs) | 29.45 | 48.75 | 86.51 | 96.5 | 113.08 | 157.4 | 171.85 | 219.76 | 242.89 | 250.75 |
| Core EBITDA Margin(%) | 26.08 | 22.53 | 21.85 | 18.56 | 24.41 | 23.87 | 28.39 | 26.93 | 25.81 | 27.58 |
| EBIT Margin(%) | 24.55 | 21.1 | 18.59 | 17.96 | 22.11 | 20.79 | 23.53 | 23.12 | 22.45 | 21.58 |
| Pre Tax Margin(%) | 17.59 | 14.33 | 14.34 | 13.1 | 13.55 | 12.33 | 20.66 | 19.21 | 16.39 | 13.77 |
| PAT Margin (%) | 13.97 | 11.14 | 11.64 | 10.01 | 10.06 | 8.67 | 14.17 | 13.54 | 11.35 | 11.13 |
| Cash Profit Margin (%) | 18.09 | 16.07 | 16.77 | 14.5 | 15.49 | 15.04 | 19.77 | 17.97 | 16.75 | 18.25 |
| ROA(%) | 8.86 | 6.25 | 4.88 | 4.32 | 3.55 | 3.54 | 5.86 | 6.5 | 4 | 3.24 |
| ROE(%) | 28.96 | 17.79 | 11.8 | 10.97 | 10.15 | 6.58 | 9.24 | 10.62 | 6.66 | 5.9 |
| ROCE(%) | 17.59 | 13.33 | 8.76 | 8.7 | 9.03 | 10 | 11.27 | 13.03 | 9.54 | 7.8 |
| Receivable days | 25.98 | 45.36 | 76.82 | 76.05 | 86.3 | 75.39 | 82.53 | 79.2 | 123.04 | 166.77 |
| Inventory Days | 90.26 | 104.4 | 146.76 | 133.88 | 169.92 | 177.63 | 230.37 | 204.46 | 245.81 | 318.37 |
| Payable days | 103.89 | 127.57 | 132.91 | 96.46 | 176.8 | 177.56 | 210.87 | 142.76 | 219.15 | 299.36 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 69.71 | 54.18 | 51.36 | 74.17 | 89.8 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 3.12 | 4.79 | 3.93 | 3.58 | 3.04 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0.1 | 0.18 | 0.29 | 0.14 | 0.1 |
| EV/Net Sales(x) | 1.09 | 1.24 | 1.46 | 1.47 | 1.64 | 6.16 | 8.22 | 5.94 | 6.96 | 6.66 |
| EV/Core EBITDA(x) | 3.59 | 4.38 | 6.16 | 6.55 | 5.97 | 22.67 | 28.29 | 21.62 | 24.99 | 23.22 |
| Net Sales Growth(%) | 0 | 0.18 | 18.89 | 46.31 | 5.46 | 53.32 | 32.42 | 49.19 | -7.92 | -2.58 |
| EBIT Growth(%) | 0 | -12.1 | -3.25 | 41.35 | 29.82 | 44.15 | 49.92 | 46.56 | -10.56 | -6.38 |
| PAT Growth(%) | 0 | -18.43 | 14.67 | 25.86 | 5.97 | 32.12 | 116.48 | 42.49 | -22.79 | -4.46 |
| EPS Growth(%) | 0 | -18.43 | 17.44 | 20.53 | 8.04 | -33.89 | 115.78 | 10.86 | -30.39 | -27.51 |
| Debt/Equity(x) | 1.89 | 1.25 | 0.95 | 1.32 | 1.38 | 0.25 | 0.46 | 0.33 | 0.38 | 0.48 |
| Current Ratio(x) | 0.94 | 1.49 | 1.27 | 1.25 | 1.12 | 2.56 | 2.43 | 2.6 | 1.69 | 1.42 |
| Quick Ratio(x) | 0.47 | 0.81 | 0.62 | 0.67 | 0.52 | 1.42 | 0.98 | 1.46 | 0.89 | 0.62 |
| Interest Cover(x) | 3.53 | 3.12 | 4.38 | 3.7 | 2.58 | 2.46 | 8.2 | 5.91 | 3.7 | 2.76 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0.08 | 0.1 | 0.08 | 0.11 | 0.16 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 61.41 | 61.26 | 61.23 | 61.23 | 61.18 | 61.18 | 61.18 | 59.07 | 59.07 | 59.07 |
| FII | 9.13 | 8.07 | 7.14 | 7.01 | 7.45 | 6.46 | 4.94 | 7.63 | 7.6 | 6.91 |
| DII | 2.51 | 2.56 | 2.57 | 2.3 | 2.3 | 2.25 | 2.24 | 1.38 | 0.42 | 0.35 |
| Public | 26.95 | 28.11 | 29.06 | 29.47 | 29.07 | 30.11 | 31.65 | 31.92 | 32.9 | 33.67 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 6.73 | 6.73 | 6.73 | 6.73 | 6.73 | 6.73 | 6.73 | 6.73 | 6.73 | 6.73 |
| FII | 1 | 0.89 | 0.78 | 0.77 | 0.82 | 0.71 | 0.54 | 0.87 | 0.87 | 0.79 |
| DII | 0.28 | 0.28 | 0.28 | 0.25 | 0.25 | 0.25 | 0.25 | 0.16 | 0.05 | 0.04 |
| Public | 2.95 | 3.09 | 3.19 | 3.24 | 3.2 | 3.31 | 3.48 | 3.63 | 3.75 | 3.83 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10.95 | 10.98 | 10.98 | 10.98 | 10.99 | 10.99 | 10.99 | 11.38 | 11.38 | 11.38 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -3% | +10% | +22% | — |
| Operating Profit CAGR | 0% | +10% | +23% | — |
| PAT CAGR | -4% | +2% | +25% | — |
| Share Price CAGR | +27% | +6% | +11% | — |
| ROE Average | +6% | +8% | +8% | +12% |
| ROCE Average | +8% | +10% | +10% | +11% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 61.41 | 61.26 | 61.23 | 61.23 | 61.18 | 61.18 | 61.18 | 59.07 | 59.07 | 59.07 |
| FII | 9.13 | 8.07 | 7.14 | 7.01 | 7.45 | 6.46 | 4.94 | 7.63 | 7.6 | 6.91 |
| DII | 2.51 | 2.56 | 2.57 | 2.3 | 2.3 | 2.25 | 2.24 | 1.38 | 0.42 | 0.35 |
| Public | 38.59 | 38.74 | 38.77 | 38.77 | 38.82 | 38.82 | 38.82 | 40.93 | 40.93 | 40.93 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 6.73 | 6.73 | 6.73 | 6.73 | 6.73 | 6.73 | 6.73 | 6.73 | 6.73 | 6.73 |
| FII | 1 | 0.89 | 0.78 | 0.77 | 0.82 | 0.71 | 0.54 | 0.87 | 0.87 | 0.79 |
| DII | 0.28 | 0.28 | 0.28 | 0.25 | 0.25 | 0.25 | 0.25 | 0.16 | 0.05 | 0.04 |
| Public | 4.23 | 4.25 | 4.26 | 4.26 | 4.27 | 4.27 | 4.27 | 4.66 | 4.66 | 4.66 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10.95 | 10.98 | 10.98 | 10.98 | 10.99 | 10.99 | 10.99 | 11.38 | 11.38 | 11.38 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.